Business Information
The group's principal activity is to develop, manufacture and market diagnostic products. The group provides rapid immunoassays or antibody-based diagnostic tests for the diagnosis of critical diseases through several product platforms. Another product triage panel for drugs of abuse is capable of detecting a broad spectrum of commonly overdosed prescription and illicit drugs in approximately 10 minutes. Triage parasite panel is designed to simultaneously detect three common waterborne parasites, giardia lamblia, cryptosporidium parvum and entamoeba histolytica/dispar, that can cause gastrointestinal infections. Triage cardiac system aids in the diagnosis of acute myocardial infarction. The group's trademarks are biosite (R), triage (R), omniclonal(R) and new dimensions in diagnosis (r).
|
|
Name |
Title
|
Email
|
| Kim Blickenstaff | Chmn., CEO | N/A | | Christopher Twomey | Sr. VP - Finance, CFO, Sec. | N/A | | Kenneth Buechler | Dir., Pres., Chief Scientific Officer | N/A | | Christopher Hibberd | Sr. VP - Corporate Development | N/A | | David Berger | VP - Legal Affairs | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 308,592 | 39,994 | | 2005 | 287,699 | 54,029 | | 2004 | 244,942 | 41,448
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
